Zimbabwe has rejected a major US healthcare agreement valued at $367m (£272m) over five years over the United States' demand for sensitive data.
This move was revealed following a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government representative later explained that the US was demanding access to genetic material for research and commercial gain while refused to share the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more negotiations to reach a agreement suitable to all parties so the nation's critical HIV programme can be sustained.
Broader Implications
This rejection follows a comparable situation in Kenya, where a court halted a similar deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to boost openness and accountability.
According to reports, 16 African countries have to date agreed to these new agreements, representing more than $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, without any equivalent assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that provided information," he stated.
"Put simply, our country would supply the raw materials for medical research without any assurance that the end products would be accessible to our citizens if a new disease outbreak arise."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending structures already established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is designed to guarantee that when a country provides its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to ongoing dialogue with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body expressed it recognised the official position, but recommended that talks need to persist considering much of the nation's HIV programmes depended on external financing.
"If specific concerns exist, including those relating to data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," it commented.
The halted deal highlights the continuing debate between receiving much-needed foreign assistance and safeguarding local interests in an increasingly interconnected world.